Article

Development of a Conformational Histamine H₃ Receptor Biosensor for the Synchronous Screening of Agonists and Inverse Agonists

Hannes Schihada,* Xiaoyuan Ma, Ulrike Zabel, Henry F. Vischer, Gunnar Schulte, Rob Leurs, Steffen Pockes, and Martin J. Lohse*

Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

ABSTRACT: The histamine H₃ receptor (H₃R) represents a highly attractive drug target for the treatment of various central nervous system disorders, but the discovery of novel H₃R targeting compounds relies on the assessment of highly amplified intracellular signaling events that do not only reflect H₃R modulation and carry the risk of high false-positive and -negative screening rates. To address these limitations, we designed an intramolecular H₃R biosensor based on the principle of bioluminescence resonance energy transfer (BRET) that reports the receptor's real-time conformational dynamics and provides an advanced tool to screen for both H₃R agonists and inverse agonists in a live cell screening-compatible assay format. This conformational G-protein-coupled receptor (GPCR) sensor allowed us to characterize the pharmacological properties of known and new H₃ receptor ligands with unprecedented accuracy. Interestingly, we found that one newly developed H₃ receptor ligand possesses even stronger inverse agonistic activity than reference H₃R inverse agonists including the current gold standard pitolisant. Taken together, we describe here the design and validation of the first screening-compatible H₃R conformational biosensor that will aid in the discovery of novel H₃R ligands and can be employed to gain deeper insights into the (in-)activation mechanism of this highly attractive drug target.

KEYWORDS: *GPCR, BRET, conformational sensor, histamine receptor, inverse agonist, drug discovery*

The group of histamine receptors belongs to the superfamily of G-protein-coupled receptors (GPCRs) and comprises four distinct subtypes, named H₁, H₂, H₃, and H₄ receptor (H₁₋₄R), that are of highest interest for modern drug discovery.[1] First, H₁R and H₂R antagonists have already been developed in the 1930s and 1970s, respectively, leading to their extensive medical use in numerous antiallergic and antiulcer pharmaceutics including loratadine (H₁R) and ranitidine (H₂R) that are listed in the WHO register of essential medicines.[2,3]

Likewise, the discovery of the subtype H₃R has raised intense hopes for the development of similarly successful drugs.[4] In humans, H₃R is almost exclusively expressed in the central nervous system (CNS) and considered to work both as an autoreceptor in presynaptic membranes and as a postsynaptic heteroreceptor controlling the release of other neurotransmitters including acetylcholine, norepinephrine, and dopamine.[5] Therefore, pharmacological modulation of the H₃R represents an attractive approach to treat various central nervous system diseases such as Parkinson's, Huntington's, and Alzheimer's diseases, as well as tic disorders.[1,6−9] In addition, pitolisant, an H₃R inverse agonist that reduces the basal signaling capacity of the receptor (known as receptor constitutive activity), has entered the market 4 years ago for

the treatment of narcolepsia.[10] Despite increasing efforts to develop novel H₃R-modulating compounds,[11−17] thus far, pitolisant represents the only H₃R ligand that is approved by health authorities. This is partially due to the limited power of our current screening technologies that are mainly based on receptor downstream signaling events. For instance, measuring compound-induced β-arrestin translocation is one of the most common assays employed in GPCR drug discovery campaigns. However, this approach not only fails to detect G-protein-biased H₃R agonists but also misses receptor inverse agonists like pitolisant. Identification of pitolisant with such a setup would instead require preincubation with selective H₃R agonists but, in turn, hamper the discovery of H₃ receptor agonists.

In contrast to these signaling-dependent assays, downstream-independent screening methods that detect ligands with distinct efficacies (e.g., agonists vs inverse agonists) and

specific downstream signaling profiles (e.g., G-protein-biased vs β-arrestin-biased agonists) would allow for the simultaneous screening of compounds with differing pharmacological profiles and thus are highly desired to speed up the discovery of novel GPCR ligands.

Conformational GPCR biosensors based on fluorescence and bioluminescence resonance energy transfer (FRET and BRET, respectively) have proven valuable tools to determine the pharmacological profiles of GPCR ligands in a real-time and live cell assay system.[18] Since the receptor's conformational change follows directly upon ligand binding without any signal amplification, this approach represents the most undistorted way to assess ligand efficacy and potency; as a consequence, these conformational readouts reveal differences among distinct test compounds where downstream-dependent assays report indiscernible activities.[19−21] Furthermore, single-cell studies employing FRET-based conformational biosensors of H_1R and H_3R have recently provided precious insights into the mechano-sensing mechanism and the activation kinetics of histamine receptors, respectively.[22,23] Recently, the suitability of such sensors for high-throughput screening has been demonstrated by employing a novel BRET system composed of the small engineered luciferase NanoLuciferase (Nluc)[24] and a red fluorescent HaloTag dye,[25] as demonstrated for two class A (α_{2A}-adrenergic and β_2-adrenergic receptor) and one class B GPCRs (parathyroid hormone receptor 1).[19]

In this study, we set out to address the urgent need for a downstream-independent and very sensitive screening platform for the highly attractive drug target, the H_3R. By fusing the BRET partners Nluc and HaloTag to this histamine receptor subtype, we generated a conformational biosensor that enabled the simultaneous detection of agonists and inverse agonists with screening-compatible assay sensitivity. Furthermore, using this biosensor, we characterized pharmacologically, in addition to several well-known H_3R standard ligands, two novel H_3R inverse agonists, which have recently been identified in a virtual screening campaign.[26] We show that one of these ligands possesses even stronger inverse agonistic activity than pitolisant and reduces the H_3R-mediated G_i-protein activity with nanomolar potencies.

■ EXPERIMENTAL SECTION

Plasmids. Wild-type human H_3R DNA (GeneID 11255) in pcDNA3.1 vector was purchased from cDNA.org. Nluc was fused at position K445 to generate C-terminally tagged H_3R_{Nluc}. Thereafter, a HaloTag was inserted between S307/G308 (full-length $H_3R_{Nluc/Halo(618)}$) or between T229/F348 ($\Delta icl3$-$H_3R_{Nluc/Halo(618)}$) within the third intracellular loop of H_3R_{Nluc}. All cloning steps were performed using the established polymerase chain reaction (PCR) strategies, and restriction enzymes and constructs were verified by sequencing (Eurofins genomics). Plasmids encoding tagged and native G-protein subunits were kindly provided by A. Inoue (Tohoku University, Sendai, Japan).

Reagents. Histamine dihydrochloride, imetit dihydrobromide, clobenpropit dihydrobromide, thioperamide, and pitolisant (BF 2649 hydrochloride) were purchased from Tocris Bioscience (Wiesbaden-Nordenstadt, Germany). Poly-D-lysine and geneticin were obtained from Sigma-Aldrich (Taufkirchen, Germany). [³H]NAMH (specific activity: 79.7 Ci/mmol) was from PerkinElmer (Waltham, MA). Z27743747 and Z3303614736 were purchased from Enamine Ltd. (Kyiv, Ukraine). The Nluc substrate furimazine and the HaloTag fluorescent dye NanoBRET 618 were obtained from Promega (Madison, WI). UR-PI294, VUF4903, VUF4904, and VUF5207 were synthesized as described previously.[27,28] White-wall, white-

bottomed 96-well microtiter plates were from Brand (Wertheim, Germany) and Gibco (Waltham, MA).

Cell Culture. HEK293T and HEK293A cells were used for the transient expression of GPCR and G-protein biosensors and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM glutamine, 10% fetal calf serum, 0.1 mg/mL streptomycin, and 100 units/mL penicillin at 37 °C with 5% CO_2. To generate the cell line stably expressing $\Delta icl3$-$H_3R_{Nluc/Halo(618)}$, HEK293A cells grown in T75 flasks were transfected at a confluence of 50% with 1 μg of DNA using Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA). Stably transfected cells were selected with 2 mg/mL geneticin and maintained in supplemented DMEM containing 500 μg/mL geneticin.

Radioligand Binding. HEK293A cells stably expressing $\Delta icl3$-$H_3R_{Nluc/Halo(618)}$ or HEK293T cells transiently transfected with 2.5 μg of the wild-type H_3R cDNA grown in 10 cm^2 culture dishes were collected (48 h after transfection for the wild-type H_3R) in cold phosphate-buffered saline (PBS) and centrifuged at 3000g for 15 min at 4 °C. The supernatant was discarded, and the cell pellet was stored at −20 °C until the day of the experiment. Prior to the experiment, cell pellets (200 μg/mL) were resuspended in binding buffer (50 mM Tris−HCl, pH 7.4) and disrupted using a Branson 250 sonifier (Boom B.V., Meppel, The Netherlands).

For saturation binding, 50 μL of cell pellets were incubated with increasing concentrations of [³H]NAMH for 2 h at 25 °C. Nonspecific binding was measured in the presence of 100 μM histamine. Equilibrium competition binding was assayed on 50 μL of cell homogenates with 2 nM [³H]NAMH in the absence and presence of increasing concentrations of unlabelled ligands for 2 h at 25 °C. To terminate incubation, homogenates were filtered over a 0.5% polyethyleneimine (PEI)-coated 96-well GF/C filter plate using a PerkinElmer 96-well Filtermate-harvester. After three rapid wash steps with ice-cold binding buffer, the GF/C filter plates were dried at 55 °C. Subsequently, 25 μL of Microscint-O scintillation liquid (PerkinElmer, Groningen, The Netherlands) was added per well and incubated for 2 h to quantify filter-bound radioactivity using a Microbeta Wallac Trilux scintillation counter (PerkinElmer).

Transient Transfection and Plating. The day before transient transfection, 1.5 × 10⁶ HEK293T (for G-protein experiments) or HEK293A cells (for H_3R conformational sensors) were seeded in T25 flasks. The next day, 1 μg of pcDNA3.1 plasmid encoding either of the two H_3R biosensors was transfected using Lipofectamine 2000. For G-protein experiments, the cells were transfected with 200 ng of LargeBit-$G_{\alpha i1}$, 1 μg of $G_{\beta 5}$-smallBit, 1 μg of $G_{\gamma 2}$, and 400 ng of wild-type H_3R plasmids. Twenty-four hours after transfection, the cells were resuspended in supplemented DMEM, mixed with 50 nM HaloTag NanoBret 618 if H_3R conformational biosensors were transfected, and transferred to poly-D-lysine-precoated white 96-well plates at a density of 50 000 cells/well.

Recording of BRET Emission Spectra. HEK293T cells were transfected and labeled as described above. Luminescence emission spectra of H_3R sensors were recorded in HBSS with 4 nm resolution upon addition of 1:1000 furimazine dilution using a CLARIOstar plate reader (BMG, Ortenberg, Germany). Spectra were normalized to the donor emission peak.

BRET and Luminescence Measurements. Cells transiently or stably expressing the H_3R biosensors or H_3R wild-type along with native and tagged G-protein subunits were washed with HBSS and incubated with 1/1000 dilution of furimazine stock solution. After incubation for 3 min at 37 °C, the basal BRET ratio (H_3R biosensor) or absolute Nluc luminescence (G-protein) was measured. Subsequently, 10 μL of 10-fold ligand solution or vehicle control was applied per well and the stimulated BRET ratio or luminescence was recorded. All experiments were conducted at 37 °C with a Synergy Neo2 (Biotek, Winooski, VT) or a CLARIOstar plate reader. Nluc emission intensity was selected using a 460/40 nm filter (Neo2) or a 450/50 nm monochromator (CLARIOstar). For HaloTag Nano-BRET 618, a 620/20 nm filter or a 620/30 nm monochromator was used. All experiments were conducted with an integration time of 0.3 s.

Scheme 1. Principle of the Sensor and Assay Design[a]

[a](a) BRET partners HaloTag and Nluc are fused to the third intracellular loop and C-terminus of the histamine H_3 receptor, respectively. The proximity of the BRET patners allows for energy transfer from the donor Nluc to HaloTag. Upon binding of full agonists or full inverse agonists, the receptor undergoes conformational changes to the fully active (top right) or inactive (bottom right) state, affecting the efficiency of energy transfer. (b) Assay protocol. (c) Insertion sites of Nluc and HaloTag in two H_3R biosensor versions.

Data Analysis and Statistics. BRET ratios were defined as acceptor emission/donor emission. Three individual luminescence or BRET values were averaged before and after ligand addition ($\text{lum}_{\text{basal}}$ and lum_{stim}; $\text{ratio}_{\text{basal}}$ and $\text{ratio}_{\text{stim}}$, respectively). To quantify ligand-induced changes, Δluminescence (Δlum) and ΔBRET were calculated for each well as a percent over basal ($[(\text{lum}_{\text{stim}} - \text{lum}_{\text{basal}})/\text{lum}_{\text{basal}}] \times 100$; $[(\text{ratio}_{\text{stim}} - \text{ratio}_{\text{basal}})/\text{ratio}_{\text{basal}}] \times 100$). Subsequently, the average Δlum/ΔBRET of vehicle control was subtracted. The Z-factors were calculated based on the following equation

$$Z - \text{factor} = 1 - \frac{(3 \times \sigma[\text{compound}] + 3 \times \sigma[\text{vehicle}])}{(\mu[\text{compound}] - \mu[\text{vehicle}])}$$

where σ and μ are the standard deviations (SDs) and average ΔBRET values of 10 μM histamine and vehicle control, respectively. For the Z-factor experiments using pitolisant as a positive control, the denominator in the equation was replaced by "$(\mu[\text{vehicle}] - \mu[\text{compound}])$".
Signal-to-noise (S/N) ratios in the Δicl3-$H_3R_{\text{Nluc/Halo(618)}}$ assay were calculated according to the following equation

$$\text{S/N} = \frac{\text{average } \Delta\text{BRET[vehicle]} - \text{average } \Delta\text{BRET[compound]}}{\text{standard deviation[vehicle]}}$$

S/N ratios in the split Nluc-based G_{i1} assay were calculated according to the following equation

$$\text{S/N} = \frac{\text{average } \Delta\text{lum[compound]} - \text{average } \Delta\text{lum[vehicle]}}{\text{standard deviation[vehicle]}}$$

Data were analyzed using Prism 5.0 software (GraphPad, San Diego, CA). The data from BRET and luminescence concentration−response experiments were fitted using a four-parameter fit. Data from radioligand saturation binding experiments were fitted using a one-site fitting model. Competition-binding curves were fitted to a one-site binding model to obtain the IC_{50} value. Equilibrium dissociation constants (K_i) of unlabeled ligands were subsequently calculated using the Cheng−Prusoff equation

$$K_i = \frac{\text{IC}_{50}}{1 + [\text{L}]/K_{\text{D}}}$$

where $[\text{L}]$ is the concentration of the labeled ligand and K_{D} is the equilibrium dissociation constant of the labeled ligand. Statistical differences were assessed by one-way ANOVA followed by Bonferroni multiple comparison or extra-sum-of-squares F-test. Differences were considered significant for values of $p < 0.05$.

■ RESULTS AND DISCUSSION

Design and Comparison of Two H_3R Conformational Biosensor Versions. The development of ligand-sensitive conformational GPCR biosensors often requires the testing of different (i) resonance energy partner combinations, (ii)

insertion sites for the FRET and BRET tags, or (iii) major modifications of the original receptor sequence.

We have previously shown that the combination of Nluc and HaloTag(618) yields the most sensitive conformational sensors for three model GPCRs[19] and therefore employed this BRET pair to create two distinct variants of conformational $H_3R_{Nluc/Halo}$ biosensors and monitor their conformational dynamics in a 96-well microtiter format (Scheme 1a,b). To minimize the manipulation of the natural H_3 receptor, we first generated a full-length H_3R sensor version by placing HaloTag between S307 and G308 in the third intracellular loop (icl3) and fusing NanoLuc to the C-terminal amino acid K445 (full-length $H_3R_{Nluc/Halo(618)}$). In some previously published conformational GPCR sensors, a long icl3, as it is also present in H_3R (142 amino acids), has been associated with issues for sensor engineering and was truncated to yield a ligand-sensitive biosensor.[29−31] Thus, in a second approach, we took advantage of a previously validated FRET-based H_3R conformational sensor design that enabled the assessment of H_3R activation kinetics in a single-cell assay format.[23] In compliance with this sensor design, we fused Nluc to K445 and placed HaloTag between amino acids T229 and F348 to generate an analogous BRET H_3R conformational sensor (Δicl3-$H_3R_{Nluc/Halo(618)}$) and monitor ligand−H_3R interaction in a 96-well microtiter format (Scheme 1c).[23]

These two sensor constructs were transiently expressed in HEK293 cells to record the luminescence emission spectra upon addition of the Nluc substrate furimazine (Figure 1a,b). Both variants displayed the typical Nluc emission maximum around 450 nm and an additional peak at 620 nm. The latter is specific for the BRET acceptor fluorophore HaloTag(618) and indicates resonance energy transfer in the basal ligand-free states of both biosensors. Subsequently, we assessed the ability of these sensor variants to detect the GPCR conformational

dynamics upon the addition of the well-characterized H_3R ligands histamine (endogenous full agonist), imetit (synthetic full agonist), clobenpropit (inverse agonist), and pitolisant (inverse agonist) (Chart 1).

We incubated HEK293 cells transiently expressing either of the two sensor versions with these reference ligands or vehicle control and recorded the resulting change in BRET over baseline in 96-well microtiter plates. These experiments revealed that the full-length $H_3R_{Nluc/Halo(618)}$ does not detect the conformational dynamics of the H_3R since no significant BRET change was observed (Figure 1c). In contrast, the BRET ratio of Δicl3-$H_3R_{Nluc/Halo(618)}$ expressing cells increased upon stimulation with the two full agonists histamine and imetit and decreased slightly after the addition of the inverse agonist pitolisant (Figure 1d).

Validation of Δicl3-$H_3R_{Nluc/Halo}$. The Δicl3-$H_3R_{Nluc/Halo(618)}$ biosensor proved capable of detecting the ligand-induced receptor conformational changes in transiently transfected HEK293 cells (Figure 1d). To evaluate the ligand-binding properties of Δicl3-$H_3R_{Nluc/Halo(618)}$, we next conducted classical radioligand saturation binding experiments. Here, binding of the radiolabeled H_3R agonist N-α-methylhistamine ([^{3}H]NAMH) saturated with a pK_D of 8.7 ± 0.2 (mean ± SD), similar to what we observed with cells expressing wild-type H_3R (pK_D = 8.9 ± 0.1) (Figure 2a and Supporting Table 1). In addition, radioligand displacement experiments at Δicl3-$H_3R_{Nluc/Halo(618)}$ with a panel of H_3R reference ligands yielded pK_i values that were in general accordance with the previously published data (Figure 2b, Supporting Table 1 and Figure 1). Importantly, Δicl3-$H_3R_{Nluc/Halo(618)}$ maintains the distinct binding affinities for the enantiomers (R)-α-methylhistamine (RAMH) and (S)-α-methylhistamine (SAMH) known from wild-type H_3R. Taken together, these binding experiments reveal that Δicl3-$H_3R_{Nluc/Halo(618)}$, similar to its original FRET analogue,[23] possesses wild-type binding properties, which represents a key requirement for its utility in ligand screening experiments.

To improve the assay's dynamic range, we next generated a HEK293 cell line stably expressing Δicl3-$H_3R_{Nluc/Halo(618)}$ and conducted live cell BRET experiments to demonstrate its suitability to study the pharmacology of H_3R ligands. Therefore, we first stimulated these sensor cells with 10 μM of six reference H_3R ligands (histamine, imetit, UR-PI294, thioperamide, clobenpropit, and pitolisant) that possess distinct intrinsic efficacies ranging from full agonism to inverse agonism (Chart 1 and Supporting Table 1). The BRET time-courses plateaued within several minutes after ligand addition and remained stable for at least 40 min (Figure 3a). The stability of the BRET response illustrates the broad time window for signal detection and underlines the applicability of this assay for automated screening conditions where stacked ligand-treated microtiter plates are read consecutively. Furthermore, all reference ligands yielded saturating BRET concentration−response curves and the EC_{50}-based order of potency resembled the pK_i-based order of affinity from our previous binding experiments (Figure 3b and Supporting Table 1). For few ligands, however, we obtained distinct affinities/ potencies using the radioligand displacement assay in cell lysates or the BRET-based conformational readout in intact cells (e.g., for clobenpropit). Similar deviations have been reported recently for H_3R ligand affinities assessed in either radioligand displacement or NanoBRET binding experiments on the very same Nluc-tagged H_3R construct.[32] Therefore, we


Figure 1. Comparison of two $H_3R_{Nluc/Halo(618)}$ biosensor versions. (a, b) Representative luminescence emission spectra of full-length $H_3R_{Nluc/Halo(618)}$ (a) and Δicl3-$H_3R_{Nluc/Halo(618)}$ (b). (c, d) BRET changes reported by full-length $H_3R_{Nluc/Halo(618)}$ (c) and Δicl3-$H_3R_{Nluc/Halo(618)}$ (d) upon addition of H_3R reference ligands. All experiments were conducted in HEK293 cells transiently transfected with the indicated biosensor. Data in (c) and (d) show pooled data from three independent experiments. *p < 0.05 vs vehicle control.

Chart 1. Chemical Structures of Histamine H₃ Receptor Agonists and Inverse Agonists Applied in This Study

H₃R agonists

histamine N^{α}-methylhistamine   imetit   impentamine

(R)-α-methylhistamine   (S)-α-methylhistamine   UR-PI294   VUF5207

H₃R inverse agonists

thioperamide   clobenpropit   pitolisant

VUF4904   VUF4903

Z27743747   Z3303614736

Figure 2. Ligand-binding properties of Δicl3-H₃R$_{\text{Nluc/Halo(618)}}$. (a) Saturation binding of the radiolabeled H₃R agonist [³H]NAMH to the wild-type H₃R and Δicl3-H₃R$_{\text{NlucHalo(618)}}$. (b) Correlation of ligand-binding affinities to the wild-type H₃R (values extracted from literature except for [³H]NAMH; see also Supporting Table 1) and Δicl3-H₃R$_{\text{NlucHalo(618)}}$ (red: agonists; blue: inverse agonists). Dotted line indicates line of unity. Experiments were conducted using membranes from transiently (a) or stably expressing (b) HEK293 cells. Data show the mean ± standard error of mean (SEM) of one representative (a) or at least three independent experiments (b).

suppose that differences in assay conditions (e.g., buffer composition or receptor environment in intact cells vs cell lysates) account for the few deviations observed in our experiments.

Of note, the three agonists histamine, imetit, and UR-PI294 elevated the BRET ratio with distinct maximal effects (E_{max}). To the best of our knowledge, this is the first data indicating that imetit behaves as a strong partial rather than a full agonist at the receptor level. In contrast to the increase in BRET evoked by agonists, the H₃R inverse agonists thioperamide, clobenpropit, and pitolisant induced a reduction in BRET, in

line with their distinct downstream effects. However, surprisingly, thioperamide, clobenpropit, and pitolisant plateaued at different BRET signals (E_{max} of pitolisant > clobenpropit > thioperamide), similar to the differences we observed for agonists, i.e., imetit and histamine. This suggests that also these ligands possess distinct inverse efficacies, with pitolisant being the strongest inverse agonist.

Next, we aimed to explore whether Δicl3-H₃R$_{\text{Nluc/Halo(618)}}$ can be utilized to conduct structure-activity-relationship (SAR) studies with H₃R ligands. We selected a panel of three chemical analogues of the H₃R agonist impentamine that present distinct chemical substitutions at the amine group (Chart 1). When characterized at the second messenger cyclic adenosine monophosphate (cAMP) level, these ligands displayed varying efficacies ranging from strong partial agonism for impentamine to inverse agonism for VUF4903 (Supporting Table 1).[28] The conformational H₃R sensor Δicl3-H₃R$_{\text{Nluc/Halo(618)}}$ detected these differential ligand activities and reported partial agonistic responses for the parent compound impentamine and its analogue VUF5207, as well as inverse agonistic responses with distinct E_{max} values for VUF4904 and VUF4903 (Figure 3c and Supporting Table 1). Overall, these results demonstrate that Δicl3-H₃R$_{\text{Nluc/Halo(618)}}$ provides a valuable tool to conduct SAR studies of H₃R ligands at the level of receptor conformation.

Last, we aimed to evaluate the sensitivity and reproducibility of this sensor cell line to screen simultaneously H₃R agonists and inverse agonists in a single high-throughput campaign (i.e., without the requirement to preincubate the cells with competing H₃R ligands). Therefore, we measured the Z-factors for agonists and inverse agonists by applying either histamine or pitolisant as a positive control, respectively.[33] The

Figure 3. Validation of the Δicl3-H$_3$R$_{Nluc/Halo(618)}$ biosensor. (a) ΔBRET time-course of six reference ligands (legend in b). (b) BRET concentration−response curves of six reference ligands. (c) Concentration−response curves of impentamine and three structural analogues. (d) Z-factors of Δicl3-H$_3$R$_{Nluc/Halo(618)}$ to assess the screening windows for H$_3$R agonists and inverse agonists. (e) BRET signals of one representative 96-well plate treated with 10 μM histamine or vehicle. (f) BRET signals of one representative 96-well plate treated with 10 μM pitolisant or vehicle. All experiments were conducted in HEK293 cells stably expressing the Δicl3-H$_3$R$_{Nluc/Halo(618)}$ biosensor. Data in (a)−(d) show the mean $\pm$ SEM of at least three independent experiments.

resulting average Z-factors were well above 0.5 (histamine: 0.58 $\pm$ 0.02; pitolisant: 0.72 $\pm$ 0.02; mean $\pm$ SEM) and showed low interday variability (histamine: 4.6%; pitolisant: 5.6%; coefficient of variation), highlighting the substantial agonist and inverse agonist screening windows and the robustness of this conformational readout (Figure 3d−f and Supporting Figure 2). These results underline the applicability of this conformational biosensor to screen for and characterize novel H$_3$R ligands with varying intrinsic activities using the same experimental setup.

Pharmacological Characterization of Two Novel H$_3$R Inverse Agonists. To further demonstrate the ability of the conformational biosensor to characterize new H$_3$R targeting compounds, we used it to assess the pharmacological properties of two new H$_3$R ligands, Z27743747 and Z3303614736 (Chart 1). These compounds were discovered in a recent in-silico docking screen and validated for binding H$_3$R with nanomolar affinities.[26] However, further information on the pharmacological properties of Z27743747 and Z3303614736 is lacking, and this is hampering a reliable evaluation of their potential as novel H$_3$R modulating lead structures. We first incubated the stable H$_3$R biosensor cell line with 10 μM of either compound and in parallel conducted the same experiments using our previously described conformational biosensor of the β_2-adrenergic receptor

(β_2AR$_{Nluc/Halo}$).[19] Both ligands evoked fast and stable negative BRET changes in H$_3$R$_{Nluc/Halo}$ expressing cells but, as control, no BRET signals were observed in β_2AR$_{Nluc/Halo}$ (Figure 4a,b).

**Figure 4.** Characterization of new H$_3$R inverse agonists. (a, b) ΔBRET time-course of Δicl3-H$_3$R$_{Nluc/Halo(618)}$ and β_2AR$_{Nluc/Halo(618)}$ upon addition of Z27743747 (a) and Z3303614736 (b). (c, d) Concentration−response curves of Z27743747 (c) and Z3303614736 (d) applied to cells expressing Δicl3-H$_3$R$_{Nluc/Halo(618)}$ or β_2AR$_{Nluc/Halo(618)}$. (e, f) ΔLuminescence time-course (e) and concentration−response (f) of the split Nluc-based G-protein sensor upon treatment with Z27743747 or Z3303614736. Experiments in (a)−(d) were conducted in HEK293 cells stably expressing either of the two conformational GPCR biosensors. Experiments in (e) and (f) were conducted in HEK293 cells transiently transfected with H$_3$R wild-type and the split Nluc-based G$_{i1}$ sensor and pre-stimulated with 300 nM histamine (for 5 min before time point 0). Data show the mean $\pm$ SEM of at least three independent experiments.

Furthermore, application of increasing compound concentrations yielded sigmoidal concentration−response curves with nanomolar EC$_{50}$-values for H$_3$R$_{Nluc/Halo}$ but not β_2AR$_{Nluc/Halo}$ (Figure 4c,d and Supporting Table 1). Of note, Z27743747 evoked an even stronger BRET response than the reference inverse agonist pitolisant (Supporting Table 1 and Figure 3), indicating that this ligand presents a promising chemical scaffold for the development of novel H$_3$R ligands with even greater intrinsic inverse agonistic activity.

To verify these data on a receptor downstream level, we employed a split luciferase complementation-based readout reflecting the G-protein activity.[34] We co-expressed G$_{\alpha i1}$ and G$_{\beta 5}$ subunits tagged with complementary Nluc fragments along with native G$_{\gamma 2}$ and wild-type H$_3$R in HEK293 cells and pre-stimulated with 300 nM histamine to induce the dissociation of the heterotrimeric G-protein complex.

Upon the addition of 10 μM Z27743747 or Z3303614736, the luminescence intensity increased and peaked within several minutes, corresponding to a reassembly of the heterotrimeric G-protein complex (Figure 4e). Moreover, these signals were

concentration-dependent and resulted in very similar IC_{50} values as measured with the H_3R conformational biosensor (Z27743747: 6.90 ± 0.11; Z3303614736: 7.03 ± 0.07; pIC_{50} ± SD) (Figure 4f and Supporting Table 1). Of note, only Z27743747, but not Z3303614736, was also able to induce an increase in G-protein luminescence when applied to basal H_3R (i.e., without 300 nM histamine preincubation) demonstrating its stronger inverse activity compared to that of Z3303614736 (Supporting Figure 4a). However, the signal-to-noise ratio (S/N) of this luminescence increase was substantially lower as compared to (i) that of histamine pre-stimulated H_3R-G_i condition and (ii) the S/N ratio assessed with Δicl3-$H_3R_{Nluc/Halo(618)}$ (also without agonist pre-stimulation) (Supporting Figure 4b).

Taken together, these results demonstrate that Z27743747 and Z3303614736 are new strong inverse agonists of H_3R that inactivate the receptor with nanomolar potencies. Additionally, comparison of the different assay systems (Δicl3-$H_3R_{Nluc/Halo(618)}$ vs H_3R wild-type plus G_{i1} sensor) underlines the accuracy and outstanding sensitivity of the new conformational H_3R biosensor to identify and characterize novel H_3R inverse agonist.

■ CONCLUSIONS

The histamine H_3 receptor is involved in multiple CNS disorders and rated among the most attractive and most targeted GPCRs by compounds in clinical trials.[35] Despite the extensive interest in regulating this receptor with new pharmaceutics, pitolisant represents so far the only approved H_3R-targeting drug partially due to the limitations of current H_3R-suited screening assays. In this work, we describe a new screening-compatible biosensor to aid in the future identification and pharmacological assessment of H_3R-modulating compounds.

Novel H_3R Conformational Biosensor Allows for the Synchronous Screening of Agonists and Inverse Agonists. This new biosensor is composed of the BRET partners Nluc and a red fluorescent HaloTag dye fused to H_3R to translate the ligand-induced conformational dynamics of this receptor into optical signals.

We show that this sensor maintains wild-type-like ligand-binding properties and facilitates the assessment of ligand potency and efficacy at the most proximal level, i.e., directly after ligand binding. Consequently, we were able to detect differences in ligand efficacies between the two H_3R agonists histamine and imetit as well as between the inverse agonists thioperamide, clobenpropit, and pitolisant (Supporting Table 1). These distinct intrinsic activities could not be observed in previous studies using the FRET-based conformational H_3R sensor[23] or downstream-dependent H_3R assays,[36] which might be a consequence of differential sensitivities of FRET- vs BRET-based sensors[37] or, with respect to histamine and imetit, be due to the impact of signal amplification in downstream-dependent assays. Supporting this hypothesis, similar discrepancies between ligand efficacies assessed with FRET vs BRET conformational sensors (UK 14 304 response at $\alpha_{2A}AR_{CFP/Flash}$ vs $\alpha_{2A}AR_{Nluc/Halo(618)}$)[19,38] and downstream vs receptor conformation assays have been reported for the α_{2A}-adrenergic (norepinephrine vs UK 14 304) and β_2-adrenergic receptor (epinephrine vs norepinephrine).[19−21] Our findings with the H_3R conformational biosensor underline the superior resolution provided by conformational GPCR sensors for the determination of ligand efficacies.

Furthermore, we demonstrate that the H_3R biosensor can be employed to explore structure−activity relationships and provides excellent sensitivity and robustness for the simultaneous screening of H_3R agonists and inverse agonists. This feature is of great value in GPCR-targeted ligand screening campaigns since, in contrast to downstream-dependent assays, no preincubation with (or subsequent addition of) an H_3R agonists is required to identify inverse agonists or vice versa.

To the best of our knowledge, such a screening-compatible and uniform assay format is not provided by any other GPCR screening technology available today.

Characterization of Novel H_3R Ligands with Marked Inverse Agonistic Efficacy. In the last part of this study, we employed the novel H_3R conformational sensor to assess the pharmacological properties of two new H_3R ligands that were recently discovered through virtual screening.[26] Both compounds bind H_3R with nanomolar affinity, but their intrinsic efficacies have not been determined so far. Interestingly, our results with the H_3R conformational biosensor revealed pronounced inverse agonistic responses of the ligands Z27743747 and Z3303614736. In particular, Z27743747 induced even higher BRET amplitudes than the validated inverse agonists thioperamide, clobenpropit, and pitolisant. This suggests that Z27743747 presents a stronger inverse agonistic activity than the current gold standard pitolisant (Supporting Table 1 and Figure 3) by stabilizing a distinct conformation of H_3R that is characterized by no or very little residual receptor signaling capacity.

Therefore, Z27743747 and Z3303614736 represent two promising H_3R lead structures with novel chemical scaffolds that can help in designing superior H_3R ligands with advantageous pharmacodynamic properties.

Taken together, this work describes the successful generation of the first screening applicable H_3R conformational sensor. This optical tool will aid in the development of novel receptor ligands and may be employed to gain new insights into the molecular mechanisms underlying H_3R conformational dynamics. The successful implementation of this sensor design for the H_3R opens up the possibility to expand this technique to other class A GPCRs, e.g., other members of the histamine receptor family, to assess the pharmacological properties of GPCR ligands directly at the level of receptor conformation.

■ ASSOCIATED CONTENT

ⓢ Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acssensors.0c00397.

Summary of H_3R ligand affinities/potencies and efficacies assessed with different assays (Table S1); competition binding of selected unlabeled H_3R ligands with [^{3}H]NAMH to cells stably expressing Δicl3-$H_3R_{NlucHalo(618)}$ (Figure S1); BRET signals and Z-factors of Δicl3-$H_3R_{Nluc/Halo(618)}$ assessed in four independent 96-well plates using histamine (Figure S2); concentration−response curves of H_3R inverse agonists assessed with Δicl3-$H_3R_{Nluc/Halo(618)}$ (Figure S3); and comparison of assay sensitivity without H_3R agonist pre-stimulation (Figure S4) (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Hannes Schihada − *Section of Receptor Biology & Signaling, Dept. Physiology & Pharmacology, Karolinska Institutet, Stockholm 171 77, Sweden; Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Würzburg 97070, Germany;* ● orcid.org/0000-0002-1889-1636; Email: hannes.schihada@ki.se

Martin J. Lohse − *Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Würzburg 97070, Germany; ISAR Bioscience, Planegg 82152, Germany; Max Delbrück Center for Molecular Medicine, Berlin 13125, Germany;* Email: m.lohse@mdc.de

Authors

Xiaoyuan Ma − *Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands*

Ulrike Zabel − *Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Würzburg 97070, Germany*

Henry F. Vischer − *Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands;* ● orcid.org/0000-0002-0184-6337

Gunnar Schulte − *Section of Receptor Biology & Signaling, Dept. Physiology & Pharmacology, Karolinska Institutet, Stockholm 171 77, Sweden;* ● orcid.org/0000-0002-2700-7013

Rob Leurs − *Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands;* ● orcid.org/0000-0003-1354-2848

Steffen Pockes − *Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Regensburg 93053, Germany*

Complete contact information is available at:
https://pubs.acs.org/10.1021/acssensors.0c00397

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): The authors declare that the University of Wuerzburg holds a patent on this technology: WO2004057333 A1.

■ ABBREVIATIONS USED

GPCR, G-protein-coupled receptor; H_3R, histamine H_3 receptor; CNS, central nervous system; FRET, fluorescence resonance energy transfer; BRET, bioluminescence resonance energy transfer; icl3, intracellular loop 3; [^{3}H]NAMH, N-α-methylhistamine; SAR, structure−activity relationship; S/N ratio, signal-to-noise ratio

■ REFERENCES

(1) Panula, P.; Chazot, P. L.; Cowart, M.; Gutzmer, R.; Leurs, R.; Liu, W. L. S.; Stark, H.; Thurmond, R. L.; Haas, H. L. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. *Pharmacol. Rev.* **2015**, *67*, 601−655.

(2) Bradshaw, J.; Brittain, R. T.; Clitherow, J. W.; Daly, M. J.; Jack, D.; Price, B. J.; Stables, R. Ranitidine (AH 19065): a new potent, selective histamine H2-receptor antagonist [proceedings]. *Br. J. Pharmacol.* **1979**, *66*, 464.

(3) Barnett, A.; Iorio, L. C.; Kreutner, W.; Tozzi, S.; Ahn, H. S.; Gulbenkian, A. Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. *Agents Actions* **1984**, *14*, 590−597.

(4) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. *Nature* **1983**, *302*, 832−837.

(5) Nieto-Alamilla, G.; Márquez-Gómez, R.; García-Gálvez, A.-M.; Morales-Figueroa, G.-E.; Arias-Montano, J.-A. The Histamine H3 Receptor: Structure, Pharmacology, and Function. *Mol. Pharmacol.* **2016**, *90*, 649−673.

(6) Ferrada, C.; Ferré, S.; Casadó, V.; Cortés, A.; Justinova, Z.; Barnes, C.; Canela, E. I.; Goldberg, S. R.; Leurs, R.; Lluis, C.; Franco, R. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. *Neuropharmacology* **2008**, *55*, 190−197.

(7) Rodríguez-Ruiz, M.; Moreno, E.; Moreno-Delgado, D.; Navarro, G.; Mallol, J.; Cortés, A.; Lluís, C.; Canela, E. I.; Casadó, V.; McCormick, P. J.; Franco, R. Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer's Disease. *Mol. Neurobiol.* **2017**, *54*, 4537−4550.

(8) Rapanelli, M. The magnificent two: histamine and the H3 receptor as key modulators of striatal circuitry. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2017**, *73*, 36−40.

(9) Rapanelli, M.; Frick, L.; Pogorelov, V.; Ohtsu, H.; Bito, H.; Pittenger, C. Histamine H3R receptor activation in the dorsal striatum triggers stereotypies in a mouse model of tic disorders. *Transl. Psychiatry* **2017**, *7*, No. e1013.

(10) Syed, Y. Y. Pitolisant: First Global Approval. *Drugs* **2016**, *76*, 1313−1318.

(11) Wágner, G.; Mocking, T. A. M.; Arimont, M.; Provensi, G.; Rani, B.; Silva-Marques, B.; Latacz, G.; Da Costa Pereira, D.; Karatzidou, C.; Vischer, H. F.; Wijtmans, M.; Kiec-Kononowicz, K.; de Esch, I. J. P.; Leurs, R. 4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity. *J. Med. Chem.* **2019**, *62*, 10848−10866.

(12) Wágner, G.; Mocking, T. A. M.; Kooistra, A. J.; Slynko, I.; Ábrányi-Balogh, P.; Keserű, G. M.; Wijtmans, M.; Vischer, H. F.; de Esch, I. J. P.; Leurs, R. Covalent Inhibition of the Histamine H3 Receptor. *Molecules* **2019**, *24*, No. 4541.

(13) Hauwert, N. J.; Mocking, T. A. M.; Da Costa Pereira, D.; Lion, K.; Huppelschoten, Y.; Vischer, H. F.; De Esch, I. J. P.; Wijtmans, M.; Leurs, R. A Photoswitchable Agonist for the Histamine H3 Receptor, a Prototypic Family A G-Protein-Coupled Receptor. *Angew. Chem., Int. Ed.* **2019**, *58*, 4531−4535.

(14) Darras, F. H.; Pockes, S.; Huang, G.; Wehle, S.; Strasser, A.; Wittmann, H. J.; Nimczick, M.; Sotriffer, C. A.; Decker, M. Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists. *ACS Chem. Neurosci.* **2014**, *5*, 225−242.

(15) Ghamari, N.; Dastmalchi, S.; Zarei, O.; Arias-Montaño, J.-A.; Reiner, D.; Ustun-Alkan, F.; Stark, H.; Hamzeh-Mivehroud, M. In silico and in vitro studies of two non-imidazole multiple targeting agents at histamine H3 receptors and cholinesterase enzymes. *Chem. Biol. Drug Des.* **2020**, *95*, 279−290.

(16) Lutsenko, K.; Hagenow, S.; Affini, A.; Reiner, D.; Stark, H. Rasagiline derivatives combined with histamine H3 receptor proper-ties. *Bioorg. Med. Chem. Lett.* **2019**, *29*, No. 126612.

(17) Łażewska, D.; Kieć-Kononowicz, K. Progress in the develop-ment of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017). *Expert Opin. Ther. Pat.* **2018**, *28*, 175−196.

(18) Lohse, M. J.; Nuber, S.; Hoffmann, C. Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. *Pharmacol. Rev.* **2012**, *64*, 299−336.

(19) Schihada, H.; Vandenabeele, S.; Zabel, U.; Frank, M.; Lohse, M. J.; Maiellaro, I. A universal bioluminescence resonance energy transfer sensor design enables high-sensitivity screening of GPCR activation dynamics. *Commun. Biol.* **2018**, *1*, No. 105.

(20) Reiner, S.; Ambrosio, M.; Hoffmann, C.; Lohse, M. J. Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. *J. Biol. Chem.* **2010**, *285*, 36188−36198.

(21) Liu, J. J.; Horst, R.; Katritch, V.; Stevens, R. C.; Wuthrich, K. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. *Science* **2012**, *335*, 1106−1110.

(22) Erdogmus, S.; Storch, U.; Danner, L.; Becker, J.; Winter, M.; Ziegler, N.; Wirth, A.; Offermanns, S.; Hoffmann, C.; Gudermann, T.; y Mederos, M. M. Helix 8 is the essential structural motif of mechanosensitive GPCRs. *Nat. Commun.* **2019**, *10*, No. 5784.

(23) Liu, Y.; Zeng, H.; Pediani, J. D.; Ward, R. J.; Chen, L.-Y.; Wu, N.; Ma, L.; Tang, M.; Yang, Y.; An, S.; Guo, X. -X.; Hao, Q.; Xu, T. R. Visualization of the activation of the histamine H3 receptor (H3R) using novel fluorescence resonance energy transfer biosensors and their potential application to the study of H3R pharmacology. *FEBS J.* **2018**, *285*, 2319−2336.

(24) Hall, M. P.; Unch, J.; Binkowski, B. F.; Valley, M. P.; Butler, B. L.; Wood, M. G.; Otto, P.; Zimmerman, K.; Vidugiris, G.; Machleidt, T.; Robers, M. B.; Benink, H. A.; Eggers, C. T.; Slater, M. R.; Meisenheimer, P. L.; Klaubert, D. H.; Fan, F.; Encell, L. P.; Wood, K. V. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. *ACS Chem Biol* **2012**, *7*, 1848−1857.

(25) Los, G. V.; Encell, L. P.; McDougall, M. G.; Hartzell, D. D.; Karassina, N.; Zimprich, C.; Wood, M. G.; Learish, R.; Ohana, R. F.; Urh, M.; Simpson, D.; Mendez, J.; Zimmerman, K.; Otto, P.; Vidugiris, G.; Zhu, J.; Darzins, A.; Klaubert, D. H.; Bulleit, R. F.; Wood, K. V. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. *ACS Chem Biol* **2008**, *3*, 373−382.

(26) Schaller, D.; Hagenow, S.; Stark, H.; Wolber, G. Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands. *PLoS One* **2019**, *14*, No. e0218820.

(27) Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R.; Buschauer, A. Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionyl-guanidine ([(3)H]UR-PI294), a high-affinity histamine H(3) and H(4) receptor radioligand. *ChemMedChem* **2009**, *4*, 225−231.

(28) Wieland, K.; Bongers, G.; Yamamoto, Y.; Hashimoto, T.; Yamatodani, A.; Menge, W. M. B. P.; Timmerman, H.; Lovenberg, T. W.; Leurs, R. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. *J. Pharmacol. Exp. Ther.* **2001**, *299*, 908−914.

(29) Vilardaga, J.-P.; Bünemann, M.; Krasel, C.; Castro, M.; Lohse, M. J. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. *Nat. Biotechnol.* **2003**, *21*, 807−812.

(30) Hoffmann, C.; Gaietta, G.; Bünemann, M.; Adams, S. R.; Oberdorff-Maass, S.; Behr, B.; Vilardaga, J.-P.; Tsien, R. Y.; Ellisman, M. H.; Lohse, M. J. A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. *Nat. Methods* **2005**, *2*, 171−176.

(31) Kauk, M.; Hoffmann, C. Intramolecular and Intermolecular FRET Sensors for GPCRs - Monitoring Conformational Changes and Beyond. *Trends Pharmacol. Sci.* **2018**, *39*, 123−135.

(32) Mocking, T. A. M.; Verweij, E. W. E.; Vischer, H. F.; Leurs, R. Homogeneous, Real-Time NanoBRET Binding Assays for the Histamine H3 and H4 Receptors on Living Cells. *Mol. Pharmacol.* **2018**, *94*, 1371−1381.

(33) Zhang, J.-H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J. Biomol. Screening* **1999**, *4*, 67−73.

(34) Inoue, A.; Raimondi, F.; Kadji, F. M. N.; Singh, G.; Kishi, T.; Uwamizu, A.; Ono, Y.; Shinjo, Y.; Ishida, S.; Arang, N.; Kawakami, K.; Gutkind, J. S.; Aoki, J.; Russell, R. B. Illuminating G-Protein-Coupling Selectivity of GPCRs. *Cell* **2019**, *177*, 1933−1947.

(35) Hauser, A. S.; Attwood, M. M.; Rask-Andersen, M.; Schioth, H. B.; Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. *Nat. Rev. Drug Discovery* **2017**, *16*, 829−842.

(36) Lim, H. D.; van Rijn, R. M.; Ling, P.; Bakker, R. A.; Thurmond, R. L.; Leurs, R. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. *J. Pharmacol. Exp. Ther.* **2005**, *314*, 1310−1321.

(37) Boute, N.; Jockers, R.; Issad, T. The use of resonance energy transfer in high-throughput screening: BRET versus FRET. *Trends Pharmacol. Sci.* **2002**, *23*, 351−354.

(38) Nikolaev, V. O.; Hoffmann, C.; Bünemann, M.; Lohse, M. J.; Vilardaga, J.-P. Molecular basis of partial agonism at the neuro-transmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. *J. Biol. Chem.* **2006**, *281*, 24506−24511.